SummaryWe surveyed practicing radiation oncologists in the United States and across the globe to understand complementary and alternative medicine (CAM) practices for the most common radiation-induced toxicities (dermatitis, fatigue, nausea, diarrhea, mucositis/xerostomia). 114 radiation oncologists from 29 different countries completed the survey. Nearly 2/3 of surveyed radiation oncologists recommend CAM for radiation-related toxicities, however, they estimated that less than 1/3 patients utilize CAM for this purpose.

Introduction {#sec1}
============

Radiation therapy (RT) is an important component in the treatment of many malignancies, and its use is anticipated to increase globally as the incidence of cancer continues to rise.[@bib1] RT can improve local tumor control and even patient survival in many settings, but its use is also associated with side effects including fatigue, pain, nausea, diarrhea, mucositis, and skin changes.

Low-grade toxicities can occur frequently with RT. For example, radiation-related fatigue has been reported to occur acutely in 80% of patients and 30% chronically.[@bib2] Prior studies suggest that many patients will use complementary and alternative medicines (CAMs) to address such side effects during and after their course of RT.[@bib3], [@bib4], [@bib5] A meta-analysis on the use of CAMs in cancer care in Western countries has shown a marked increase in its use from an estimated 25% in the 1970s to 49% after 2000.[@bib6] Yet, little is known about the use of CAMs for the treatment of RT toxicities, the types of CAMs employed in this capacity, physician attitudes toward this application of CAMs, or global variation in these practices and perspectives.

The management of toxicity associated with RT is an integral part of a patient's cancer treatment course. However, studies have shown that 47% to 71% of patients do not discuss CAMs with their physicians.[@bib7], [@bib8], [@bib9] Qualitative studies have reported a variety of CAM practices among patients who receive RT, including the use of oral supplements, mind-body techniques, and cognitive-behavioral therapies. A discussion on the safety, efficacy, or interaction with RT for any given CAMs are often difficult owing to a broad lack of evidence pertaining to the potential risks and benefits of these approaches.

In this study, we developed and administered a survey to obtain information from radiation oncology providers internationally with regard to the use of CAMs among their patients and their own perceptions regarding the use of CAMs for RT toxicities.

Methods and Materials {#sec2}
=====================

We created a cross-sectional, descriptive survey using a combination of dichotomous, scalar, multiple-choice, and free-response questions ([Appendix](#appsec1){ref-type="sec"}). The study design and survey questions were evaluated by the University of Wisconsin-Madison Institutional Review Board and were determined to be exempt under category 45 CFR 46.101(b)(2) (UW16-1342). The survey respondents were anonymous, and the survey began with a statement of informed consent.

CAMs were defined per the National Cancer Institute guidelines as approaches referring to practices that are used together with or in place of conventional treatments or medicines.[@bib10] Demographic information gathered included only the provider's practice location, location of training, and number of years in practice. Respondents were asked about their practice of recommending CAMs for RT toxicity, perceptions of the efficacy of CAMs for RT toxicity, the percentage of their patients estimated to use CAMs for RT toxicities, and sources/barriers to information on CAMs. Finally, 5 toxicity-specific sections (ie, skin, fatigue, nausea, diarrhea, and mucositis/dry mouth) evaluated specific applications of CAMs for RT toxicity and collected information on the specific types of CAM employed.

Surveys were distributed to 1174 practicing radiation oncologists, including trainees in residency. The survey was administered electronically via e-mail using the SurveyMonkey web application. Three reminder emails were sent, and the electronic survey was closed 6 months after the initial e-mail. To increase response from providers outside of North America, a cohort of printed surveys were distributed and collected anonymously (n = 100) at the 2017 American Society for Radiation Oncology (ASTRO) annual meeting international breakfast.

The distribution of survey responses was tabulated, and demographic data regarding the duration of practice and location were compared between those who would and would not recommend CAMs using the χ^2^ test. Statistical tests were 2-sided, and 5% (*P* \< .05) was set as the level of significance. The analysis was done using the statistical software R package, version 3.4.2. The responses with regard to practice patterns and perceptions were further tabulated based on region of practice and duration of practice. The specific CAM remedies used were tabulated by location to evaluate whether the use of specific remedies were regionalized.

Results {#sec3}
=======

A total of 125 responses (11.0%) were obtained from the 1174 surveys. A total of 47 paper surveys (37.6%) were collected at the ASTRO Annual Meeting international breakfast, and the remainder were received through SurveyMonkey. Eleven physician respondents did not give consent to participate in the study, which left 114 completed surveys (10.0%) to be analyzed from 29 different countries. There was a balanced distribution between North American (n = 56) and non-North American (n = 58) providers. Five surveys (4.4%) were collected from providers practicing in Africa, 22 (19.3%) in Asia/Australia, 6 (5.3%) in Europe, 63 (55.3%) in North America, and 18 (15.8%) in South America ([Table 1](#tbl1){ref-type="table"}). Among the responding clinicians, 63.0% recommended CAMs in their practice.Table 1Participant characteristicsCountry of practiceCountry of trainingAfrica, n (%)5 (4.4)4 (3.5) Egypt11 Ghana11 Nigeria22 Zambia1-Asia/Australia, n (%)22 (19.3)20 (17.6) Bangladesh11 China66 India34 Japan11 Malaysia1- Philippines11 Saudi Arabia1- South Korea22 Taiwan33 Turkey21Europe, n (%)6 (5.3)11 (7.9) France-1 Netherlands11 Poland11 Spain13 Sweden33 United Kingdom-2North America, n (%)63 (55.3)61 (53.5) Canada34 Mexico53 United States of America5554South America, n (%)18 (15.8)14 (12.3) Argentina33 Brazil107 Chile22 Colombia1- Venezuela22Unknown/missing, n (%)-4 (3.5)Total114114

Overall, providers reported that 29.4% of their patients use CAMs, and 87.7% encouraged or were neutral on CAM use, but 12.3% recommended stopping CAMs. The most common sources of patient information on CAMs were the Internet (75.4%), friends (60.5%), and family (58.8%). Clinicians reported the highest use of CAMs for RT skin toxicity at 66.7%, with reported CAM use rates of 48.2% for fatigue, 40.4% for nausea, 36.8% for mucositis/xerostomia, and 21.9% for diarrhea.

These responses were further stratified based on region of practice. The average percent use of CAMs was 21.3% in Africa, 25.0% in Asia/Australia, 17.0% in Europe, 28.8% in North America, and 41.9% in South America ([Table 2](#tbl2){ref-type="table"}). The region that encouraged the use of CAMs the most was North America at 53.3%, and the region that encouraged patients to stop the use of CAMs the most was Asia/Australia at 35.7%. Taken altogether, providers felt neutral about the effectiveness of CAMs (36.8%).Table 2Distribution of responses from CAM survey by region of practiceTotal N (%)Africa, n (%)Asia/Australia, n (%)Europe, n (%)North America, n (%)South America, n (%)How effective are CAM remedies for your patients for the treatment of radiation toxicities? 1 (not effective)12 (10.5)0 (0)4 (33.3)2 (16.7)4 (33.3)2 (16.7) 220 (17.5)1 (5.0)6 (30.0)2 (10.0)10 (50.0)1 (5.0) 342 (36.8)2 (4.8)9 (21.4)2 (4.8)24 (57.1)5 (11.9) 419 (16.7)0 (0)1 (5.3)0 (0)11 (57.9)7 (36.8) 5 (very effective)5 (4.4)0 (0)0 (0)0 (0)3 (60.0)2 (40.0) No response16 (14.0)\-\-\-\--Average percent use of CAM by patients29.4%21.3%25.0%17.0%28.8%41.9%What is your practice's general perception of CAM? We encourage patients to continue using CAM30 (26.3)0 (0)5 (16.7)1 (3.3)16 (53.3)8 (26.7) We are neutral about patient's use of CAM70 (61.4)2 (2.9)12 (17.1)3 (4.3)43 (61.4)10 (14.3) We encourage patients to stop using CAM14 (12.3)3 (21.4)5 (35.7)2 (14.3)4 (28.6)0 (0)What are the sources of patient's information regarding CAM? Magazines/print media38 (33.3)2 (5.3)8 (21.1)3 (7.9)24 (63.2)1 (2.6) Internet86 (75.4)4 (4.7)17 (19.8)5 (5.8)50 (58.1)10 (11.6) Medical professionals38 (33.3)0 (0)7 (18.4)1 (2.6)20 (52.6)10 (26.3) Practitioners of alternative medicine56 (49.1)3 (5.4)5 (8.9)5 (8.9)37 (66.1)6 (10.7) Religious influences23 (20.2)4 (17.4)6 (26.1)0 (0)13 (56.5)0 (0) Friends69 (60.5)3 (4.3)10 (14.5)5 (7.2)45 (65.2)6 (8.7) Family67 (58.8)5 (7.5)13 (19.4)4 (6.0)41 (61.2)4 (6.0) Other cancer patients59 (51.8)4 (6.8)10 (16.9)3 (5.1)32 (54.2)10 (16.9)What are some reasons that patients approach you about their use of CAM? They are concerned about drug interactions50 (43.9)3 (6.0)12 (24.0)5 (10.0)25 (50.0)5 (10.0) They want their doctor to be fully informed about their health56 (49.1)2 (3.6)4 (7.1)5 (8.9)39 (69.6)6 (10.7) They want to know more about CAM62 (54.4)2 (3.2)10 (16.1)3 (4.8)41 (66.1)6 (9.7) They would only take it with doctor's approval51 (44.7)4 (7.8)9 (17.6)4 (7.8)24 (47.1)10 (19.6)What are some reasons that you believe patients may not approach physicians about CAM treatments? Doctor's response would be negative95 (83.3)5 (5.3)15 (15.8)5 (5.3)55 (57.9)15 (15.8) Doctor would not know sufficient information about CAM51 (44.7)3 (5.9)8 (15.7)0 (0)33 (64.7)7 (13.7) Not important for doctor to know21 (18.4)0 (0)2 (9.5)1 (4.8)17 (81.0)1 (4.8) My doctor never asks me about CAM31 (27.2)0 (0)1 (3.2)2 (6.5)24 (77.4)4 (12.9)Do your patients use CAM remedies for the following effects of radiation therapy? Skin toxicity76 (66.7)1 (1.8)12 (21.8)2 (2.6)48 (63.2)13 (17.1) Fatigue55 (48.2)1 (1.8)12 (21.8)3 (5.5)32 (58.2)7 (12.7) Nausea46 (40.4)2 (4.3)6 (13.0)1 (2.2)31 (67.4)6 (13.0) Diarrhea25 (21.9)1 (4.0)3 (12.0)1 (4.0)17 (68.0)3 (12.0) Mucositis/dry mouth42 (36.8)1 (2.4)12 (28.6)1 (2.4)21 (50.0)7 (16.7) None9 (7.9)1 (11.1)1 (11.1)0 (0)5 (55.6)2 (22.2)[^2]

The reasons why physicians felt that patients would approach them about CAM use were well distributed, with 43.9% indicating a concern about drug interactions, 49.1% wanting physicians to be fully informed of their health, 54.4% wanting to know more about CAMs, and 44.7% wanting to take CAMs only with their doctor's approval. The most common reason physicians cited for why a patient would not approach them was that the doctor's response would be negative (83.3%; [Table 2](#tbl2){ref-type="table"}).

The proportion of clinicians who recommend CAMs for RT toxicities did not vary significantly when stratified by provider's number of years in practice (*P* = .23) or location (United States/Canada vs other; *P* = .74; [Table 3](#tbl3){ref-type="table"}). Among physicians who recommended CAMs, 30.6% were \<5 years in practice, 19.4% had 5 to 10 years of experience, 29.2% were 10 to 20 in practice, and 20.8% had \>20 years of experience (*P* = .23). When stratified by years of provider experience, the responses did not appear to differ between the cohorts ([Table 4](#tbl4){ref-type="table"}).Table 3Participant characteristics and CAM recommendationsVariableDoes not recommend CAM, n (%); (n = 42)Recommends CAM, n (%); (n = 72)*P*-valueDuration of Practice, n (%).23 \<5 y14 (38.9)22 (61.1) 5-10 y7 (33.3)14 (66.7) 10-20 y9 (30.0)21 (70.0) \>20 y12 (44.4)15 (55.6)American/Canadian radiation oncologist.74 Yes20 (34.5)38 (65.5) No22 (39.3)34 (60.7)[^3]Table 4Distribution of responses from CAM survey by duration of practiceTotal N (%)\<5 y, n (%)5-10 y, n (%)10-20 y, n (%)\>20 y, n (%)How effective are CAM remedies for your patients for the treatment of radiation toxicities? 1 (not effective)12 (10.5)4 (12.5)2 (12.5)2 (8)4 (16) 220 (17.5)10 (31.2)0 (0)6 (24)4 (16) 342 (36.8)14 (43.8)9 (56.25)9 (36)10 (40) 419 (16.7)2 (6.25)4 (25)7 (28)6 (24) 5 (very effective)5 (4.4)2 (6.25)1 (6.25)1 (4)1 (4) No response16 (14.0)\-\-\--Average percent use of CAM by patients29.4%29.3%28.3%29.3%30.3%What is your practice's general perception of CAM? We encourage patients to continue using CAM30 (26.3)9 (30.0)6 (20.0)8 (26.7)7 (23.3) We are neutral about patient's use of CAM70 (61.4)23 (32.9)12 (17.1)19 (27.1)16 (22.9) We encourage patients to stop using CAM14 (12.3)4 (28.6)3 (21.4)3 (21.4)4 (28.6)What are the sources of patient's information regarding CAM? Magazines/print media38 (33.3)13 (34.2)9 (23.7)9 (23.7)7 (18.4) Internet86 (75.4)30 (34.9)17 (19.8)20 (23.3)19 (22.1) Medical professionals38 (33.3)12 (31.6)9 (23.7)10 (26.3)7 (18.4) Practitioners of alternative medicine56 (49.1)18 (32.1)12 (21.4)12 (21.4)14 (25.0) Religious influences23 (20.2)13 (56.5)3 (13.0)3 (13.0)4 (17.4) Friends69 (60.5)27 (39.1)9 (13.0)19 (27.5)14 (20.3) Family67 (58.8)25 (37.3)10 (14.9)18 (26.9)14 (20.9) Other cancer patients59 (51.8)19 (32.2)13 (22.0)14 (23.7)13 (22.0)What are some reasons that patients approach you about their use of CAM? They are concerned about drug interactions50 (43.9)16 (32.0)12 (24.0)10 (20.0)12 (24.0) They want their doctor to be fully informed about their health56 (49.1)18 (32.1)12 (21.4)12 (21.4)14 (25.0) They want to know more about CAM62 (54.4)24 (38.7)13 (21.0)14 (22.6)11 (17.7) They would only take it with doctor's approval51 (44.7)18 (35.3)11 (21.6)12 (23.5)10 (19.6)What are some reasons that you believe patients may not approach physicians about CAM treatments? Doctor's response would be negative95 (83.3)31 (32.6)16 (16.8)25 (26.3)23 (24.2) Doctor would not know sufficient information about CAM51 (44.7)18 (35.3)10 (19.6)13 (25.5)10 (19.6) Not important for doctor to know21 (18.4)5 (23.8)6 (28.6)5 (23.8)5 (23.8) My doctor never asks me about CAM31 (27.2)10 (32.3)4 (12.9)8 (25.8)9 (29.0)Do your patients use CAM remedies for the following effects of radiation therapy? Skin toxicity76 (66.7)25 (32.9)12 (15.8)20 (26.3)19 (25.0) Fatigue55 (48.2)16 (29.1)11 (20.0)12 (21.8)16 (29.1) Nausea46 (40.4)13 (28.3)11 (23.9)12 (26.1)10 (21.7) Diarrhea25 (21.9)10 (40.0)4 (16.0)8 (32.0)3 (12.0) Mucositis/dry mouth42 (36.8)17 (40.5)3 (7.1)13 (31.0)9 (21.4) None9 (7.9)3 (33.3)3 (33.3)1 (11.1)2 (22.2)[^4]

Among providers who believed CAMs were not effective on the Likert scale, the highest percentage was with those with the most experience (\>20 years; 16%), and among providers who believed CAMs were the most effective, the highest percentage was among those with the least experience (\<10 years; 12.5%). The reasons for why physicians felt that patients would approach them about CAM use were distributed similarly between the groups when physicians were stratified by experience ([Table 4](#tbl4){ref-type="table"}).

CAM remedies for RT toxicities were reported by free response and further classified by region of practice. The most common CAM remedies reported were aloe vera (n = 20) and Chinese traditional medicine (n = 4) in Asia/Australia; aloe vera (n = 20) and exercise/yoga (n = 14) in North America; and aloe vera (n = 7) and chamomile (n = 9) in South America ([Table 5](#tbl5){ref-type="table"}). Regions with limited responses were not included.Table 5Remedies for specific toxicities by regionAsia/Australia (n)North America (n)South America (n)SkinAloe vera (20)\
Chinese traditional medicine (2)Aloe vera (18)\
Essential oils (9)\
Vitamin E (8)\
Calendula cream (6)Aloe vera (7)\
Chamomile (6)FatigueChinese traditional medicine (3)\
Supplements (2)Exercise/yoga (14)\
Supplements (8)\
Ginseng (3)Fruit (2)\
Acupuncture (2)\
Herbs (2)NauseaGinger (2)\
Acupuncture (1)Ginger (9)\
Marijuana (9)\
Acupuncture (7)Acupuncture (2)\
Tea (2)Diarrhea-Probiotics (11)Nutmeg (2)MucositisHoney (2)Acupuncture (7)\
Salt/baking soda (3)\
Aloe vera (2)Chamomile (3)\
Acupuncture (1)

Discussion {#sec4}
==========

In this cross-sectional descriptive study of international radiation oncology providers, we found that nearly two-thirds of radiation oncologists recommended CAMs for RT-related toxicities. However, these providers estimated that less than one-third of patients use CAMs for this purpose, which is slightly lower than in previous reports. Few prior studies have reported on the use of CAMs among patients receiving RT.[@bib4], [@bib5], [@bib7], [@bib11] One study of patients from Asia undergoing RT for various malignancies found that 86% were using CAMs.[@bib7]

A multicenter, prospective study of patients with breast cancer who received RT in the United States found that 54% reported CAM usage.[@bib5] On the other hand, international studies have been published citing widely varying rates (32%-98%) of CAM use among patients with cancer.[@bib12], [@bib13], [@bib14] This wide variation in reported CAM usage may result from differences in study design, phrasing of survey questions, the surveyed population, and the definition of CAMs used. For example, patient reports could differ from physician reports of perceived patient CAM use, and definitions of CAMs may vary depending on the context of the study and the population of interest. In the current analysis, the definition by the National Cancer Institute was used. The relatively limited variation in our study in the reported usage of CAMs across regions and by provider experience could suggest that these factors may have a limited, if any, role in contributing to the variability of CAM usage reported in prior studies.

Although the incidence of cancer has been increasing in the developing world, very little data are available on the management of RT-related toxicities in developing countries and the potential discrepancy between treatment approaches in resource-poor and resource-rich practice environments. Our study suggests that CAMs are used at comparable rates across a wide range of practice settings internationally. This prevalence may be due to a long-standing history of CAM use among patients with cancer, which may translate into a greater awareness among oncologists. Still, the remedies used for the specific toxicities vary, and this may be attributed to different sociocultural and medical systems.

A limited number of studies have evaluated the efficacy or safety of CAM remedies for RT toxicities. In a phase 3 trial, patients undergoing concurrent chemoradiotherapy for head and neck cancer were randomized to prophylactic trolamine emulsion (active ingredient in sunscreen) every 8 hours, 4 hours apart from the RT session or best supportive care. Grade 3 skin reactions occurred in 20% of the treatment group and 53.3% of the control group (P \< .01), demonstrating a significant benefit in the prevention of skin RT toxicity.[@bib11] A phase 3, randomized clinical trial found improved breast tissue compliance in patients who received pentoxifylline and vitamin E versus placebo after breast RT.[@bib15] A recent study examined the effect of topical vitamin D compared with standard aqua cream in patients with breast cancer who received daily RT. Vitamin D was well tolerated with no increased side effects, and radiation dermatitis was not significantly different between both treatment arms.[@bib16]

Other reports have suggested that CAMs can have a detrimental effect when used with RT. A case report published in 2002 discussed a patient who was scheduled to receive magnetic resonance imaging--guided prostate brachytherapy. Before the procedure, the prothrombin time was found to be elevated, and the procedure was canceled. The patient had been self-administering supraphysiologic doses of niacin, which caused his increased prothrombin time and could have led to a life-threatening intraoperative hemorrhage.[@bib17] Combining these limited studies on the efficacy of CAMs together with the results of our current survey and in the absence of evidence-based data, most surveyed radiation oncologists appear to view CAMs favorably with regard to the treatment of RT toxicities. This could suggest a broad need for further prospective evaluations of the safety and efficacy of CAMs because the most commonly used CAMs have not been well studied together with RT.

Although CAM remedies can have beneficial or deleterious effects on patients when used in combination with traditional therapies, prior studies have found that the majority of patients do not mention the use of CAMs to their doctors. This was mostly because their doctors did not ask about the use of CAMs.[@bib14], [@bib18] In our study, providers most often thought that patients did not approach them because their response would be negative (83.3%) or that they would not know sufficient information about CAMs (44.7%). Prior survey studies of patients with cancer have found that these are common sentiments, and 2 studies showed that less than half of patients knew a physician with competence in CAMs.[@bib19], [@bib20]

Interestingly, the present analysis found that approximately two-thirds of radiation oncologists recommended CAMs with only 12.3% of providers discouraging their use. This trend did not significantly vary when stratified by provider's number of years in practice or by location. Nevertheless, the surveyed radiation oncologists estimated that 29% of their patients use CAMs, a low estimate compared with other studies. The findings from the present study could highlight a need for a more open discussion because radiation oncologists are more aware of and open to the utilization of CAMs than patients may realize.

In our study, the most commonly reported CAM remedies were aloe vera products (n = 45) for skin toxicity, exercise (n = 14) for fatigue, ginger (n = 11) for nausea, probiotics (n = 11) for diarrhea, and acupuncture (n = 8) for mucositis/xerostomia. Intriguingly, the rates of CAM recommendation did not markedly vary by region, but the specific types of CAMs used for RT toxicities varied widely between regions. Such differences may be related to CAM availability as well as cultural, social, and economic influences.

In other studies, the most commonly cited CAMs used by patients with cancer included exercise therapy, ingestion of vitamins and minerals, and herbal therapies.[@bib21], [@bib22] Given the potential interactions that could occur with the use of oral supplements, the findings of our study suggest that the highest usage of topical or activity-based CAMs together with RT may offer some reassurance about the relative safety of current practices. However, further evaluation is needed.

Our study has several limitations, and perhaps the most notable is the low response rate. Several factors may have contributed to this. First, we surveyed a diverse group of responders from 29 different countries. Survey questions were written in English and may have been more difficult for nonnative English speakers to understand. In addition, recipient contact information was not verified, and we are not able to determine how many survey emails were actually received, opened, or read. To increase the response rate from non-North American providers, paper surveys were collected at the ASTRO Annual Meeting international breakfast; thus, there may be differences related to the distribution of surveys at 2 different time points with 2 different formats (paper and online), which may be unaccounted for in our analysis. Because of the low response rate, there is potential for selection bias in this study among the responding practitioners who completed this survey. However, other physician survey studies have observed similarly low response rates and have suggested that the response rate in this population may not be a reliable proxy for response bias.[@bib23], [@bib24], [@bib25]

Despite these limitations, this study provides initial insights on a poorly understood topic that may influence the care of a majority of patients with cancer globally, and highlights a need for further research. A recent study conducted using the National Cancer Database illustrates this need and reports that patients who received CAMs are more likely to refuse conventional treatments, which is associated with a higher risk of death.[@bib26] Our findings are hypothesis-generating and may guide subsequent investigations into the use of CAMs among patients who receive radiation, especially in developing countries.

Knowledge often transfers from developed countries that perform clinical studies to less affluent settings, but the understanding of local and regional CAM applications for RT toxicities may enable a critical transfer of knowledge from resource-poor settings to developed nations for the collective benefit of patients with cancer. Such knowledge will be critical given that a minority of patients discuss CAMs with their doctors, despite the potential positive or negative impact on the overall cancer care. Future work could include interventional studies in which radiation oncologists initiate a discussion of CAMs with their patients.

Conclusions {#sec5}
===========

The use of CAMs to treat common RT toxicities is prevalent globally, with nearly two-thirds of radiation oncologists recommending CAMs for RT-related toxicities. There appears to be broad awareness of and support for CAM usage among radiation oncology providers; however, patients may not perceive this. Open discussions of CAMs before or during the course of RT may maximize the potential benefits of CAMs in the treatment of RT toxicities.

Supplementary data {#appsec1}
==================
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